To Kenneth K W, Zhan Zhirong, Litman Thomas, Bates Susan E
Molecular Therapeutics Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bldg. 10, Room 13N220, 10 Center Drive, Bethesda, MD 20892-4255, USA.
Mol Cell Biol. 2008 Sep;28(17):5147-61. doi: 10.1128/MCB.00331-08. Epub 2008 Jun 23.
ABCG2 is recognized as an important efflux transporter in clinical pharmacology and is potentially important in resistance to chemotherapeutic drugs. To identify epigenetic mechanisms regulating ABCG2 mRNA expression at its 3' untranslated region (3'UTR), we performed 3' rapid amplification of cDNA ends with the S1 parental colon cancer cell line and its drug-resistant ABCG2-overexpressing counterpart. We found that the 3'UTR is >1,500 bp longer in parental cells and, using the miRBase TARGETs database, identified a putative microRNA (miRNA) binding site, distinct from the recently reported hsa-miR520h site, in the portion of the 3'UTR missing from ABCG2 mRNA in the resistant cells. We hypothesized that the binding of a putative miRNA at the 3'UTR of ABCG2 suppresses the expression of ABCG2. In resistant S1MI80 cells, the miRNA cannot bind to ABCG2 mRNA because of the shorter 3'UTR, and thus, mRNA degradation and/or repression on protein translation is relieved, contributing to overexpression of ABCG2. This hypothesis was rigorously tested by reporter gene assays, mutational analysis at the miRNA binding sites, and forced expression of miRNA inhibitors or mimics. The removal of this epigenetic regulation by miRNA could be involved in the overexpression of ABCG2 in drug-resistant cancer cells.
ABCG2被公认为临床药理学中一种重要的外排转运蛋白,在化疗药物耐药性方面可能具有重要意义。为了确定在其3'非翻译区(3'UTR)调节ABCG2 mRNA表达的表观遗传机制,我们用S1亲本结肠癌细胞系及其耐药的ABCG2过表达对应细胞系进行了3' cDNA末端快速扩增。我们发现亲本细胞中3'UTR比耐药细胞中长>1500 bp,并且使用miRBase TARGETs数据库,在耐药细胞中ABCG2 mRNA缺失的3'UTR部分鉴定出一个推定的微小RNA(miRNA)结合位点,该位点与最近报道的hsa-miR520h位点不同。我们推测推定的miRNA在ABCG2的3'UTR处结合会抑制ABCG2的表达。在耐药的S1MI80细胞中,由于3'UTR较短,miRNA无法与ABCG2 mRNA结合,因此,mRNA降解和/或蛋白质翻译抑制得以缓解,导致ABCG2过表达。通过报告基因检测、miRNA结合位点的突变分析以及强制表达miRNA抑制剂或模拟物对这一假设进行了严格验证。miRNA去除这种表观遗传调控可能与耐药癌细胞中ABCG2的过表达有关。